Viking Therapeutics (VKTX) will report its second-quarter earnings on Jul 24, after market closes. Since the company lacks a marketed drug in its portfolio, we do not expect any revenues. The Zacks Consensus Estimate for earnings is pegged at a loss of 26 cents per share.Viking’s loss estimates have increased from $1.08 per share to$1.11 for 2024 and from $1.42 to$1.45 for 2025 in the past 60 days. Image Source: Zacks Investment ResearchEarnings Surprise HistoryThe biotech firm’s performance has been mixe ...